Provided By GlobeNewswire
Last update: Aug 14, 2025
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025
Read more at globenewswire.comNASDAQ:GCTK (8/26/2025, 11:33:33 AM)
4.3963
-0.47 (-9.73%)
Find more stocks in the Stock Screener